Expert opinion on the introduction of the meningococcal B (4CMenB) vaccine in the EU/EEA
This expert opinion is intended to support national decision-making by summarising the considerations and concerns of some EU/EEA countries when they discussed whether to introduce the 4CMenB vaccine into their national immunisation programmes.
EIW 2015 at ECDC
On the occasion of the tenth anniversary of European Immunization Week, ECDC is releasing a new complement of data, tools, blogs and updates to support public health authorities in their work against vaccine preventable diseases.
Surveillance of invasive bacterial diseases in Europe, 2012
This report describes the occurrence of invasive bacterial diseases (IBD) in Europe during 2012, based on data collected through The European Surveillance System (TESSy).
Invasive bacterial diseases - Annual Epidemiological Report 2014 [2012 data]
This report presents the epidemiological situation for vaccine-preventable diseases – invasive bacterial diseases (invasive Haemophilus influenzae, meningococcal and pneumococcal disease) as of 2012 and describes the statistical and epidemiological methods used.
External quality assessment scheme 2011 for Neisseria meningitidis
This report on EQA performance shows that European Reference Laboratories for Meningococci differ in their capacities and the level of characterisation of the distributed N. meningitidis material, but that there have been improvements since the first ECDC IBD-labnet distribution.
ECDC Vaccine Scheduler
The Vaccine Scheduler is an interactive tool that shows vaccination schedules for individual EU/EEA countries and specific age groups.
- Hepatitis A
- Hepatitis B
- Human papillomavirus infection
- Influenza in humans, seasonal
- Invasive Haemophilus influenzae disease
- Meningococcal disease
- Pneumococcal disease
- Prevention and control
- Rotavirus infection
- Tick-borne diseases
Impact on disease incidence of a routine universal and catch-up vaccination strategy against Neisseria meningitidis C in Tuscany, ItalyArchived
Findings in this study confirmed the herd immunity effect of immunizing young children, since invasive meningococcal disease was not only reduced among vaccinees, but in all age groups.
Immunogenicity and tolerability of recombinant serogroup B meningococcal vaccine administered with or without routine infant vaccinations according to different immunization schedules – A randomized controlled trialArchived
4CMenB has the potential to reduce serogroup B meningococcal disease substantially. Despite its potential, the vaccine may have some limitations, and it remains to be seen if booster doses will be required to sustain protection.